Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria

Elisa Rumi, Emanuela Boveri, Marta Bellini, Daniela Pietra, Virginia V. Ferretti, Emanuela Sant'Antonio, Chiara Cavalloni, Ilaria C. Casetti, Elisa Roncoroni, Michele Ciboddo, Pietro Benvenuti, Benedetta Landini, Elena Fugazza, Daniela Troletti, Cesare Astori, Mario Cazzola, on Behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The recently revised World Health Organization (WHO) classification of myeloid neoplasms recognizes prefibrotic myelofibrosis (prePMF) as a distinct entity, characterized by well-defined histopathologic features together with minor clinical criteria (leukocytes, anemia, increased LDH, splenomegaly). The aim of the study was to examine the clinical relevance of distinguishing prePMF from essential thrombocythemia (ET). We identified in our database all patients affected with ET, prePMF and primary myelofibrosis (PMF) diagnosed according to 2008 WHO criteria with a bone marrow fibrosis grade 0-1 at diagnosis and one DNA sample to define the mutational status. The bone marrow morphology of all 404 identified patients was reviewed by an expert pathologist and patients were reclassified according to the 2016 WHO criteria. After reclassification, our cohort included 269 ET, 109 prePMF, and 26 myeloproliferative neoplasm unclassificable. In comparison with ET, patients with prePMF had higher leukocyte count, lower hemoglobin level, higher platelet count, higher LDH values, and higher number of circulating CD34-positive cells; they showed more frequently splenomegaly (all P values < ·001). CALR mutations were more frequent in prePMF than in ET (35·8% vs 17·8%, P < ·001). PrePMF patients had shorter overall survival (P < ·001) and a trend to a higher incidence of leukemic evolution (P ·067) compared to ET patients, while they did not differ in terms of thrombotic and bleeding complications. In conclusion, ET and prePMF diagnosed according to 2016 WHO criteria are two entities with a different clinical phenotype at diagnosis and a different clinical outcome.

Original languageEnglish
Pages (from-to)101735-101744
Number of pages10
JournalOncotarget
Volume8
Issue number60
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Essential Thrombocythemia
Primary Myelofibrosis
Splenomegaly
Platelet Count
Leukocyte Count
Anemia
Neoplasms
Hemoglobins
Leukocytes
Bone Marrow
Databases
Hemorrhage
Phenotype
Mutation
Survival
DNA
Incidence

Keywords

  • Diagnostic criteria
  • Myelofibrosis
  • Prefibrotic
  • Thrombocythemia
  • WHO

ASJC Scopus subject areas

  • Oncology

Cite this

Rumi, E., Boveri, E., Bellini, M., Pietra, D., Ferretti, V. V., Sant'Antonio, E., ... on Behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators (2017). Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. Oncotarget, 8(60), 101735-101744. https://doi.org/10.18632/oncotarget.21594

Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. / Rumi, Elisa; Boveri, Emanuela; Bellini, Marta; Pietra, Daniela; Ferretti, Virginia V.; Sant'Antonio, Emanuela; Cavalloni, Chiara; Casetti, Ilaria C.; Roncoroni, Elisa; Ciboddo, Michele; Benvenuti, Pietro; Landini, Benedetta; Fugazza, Elena; Troletti, Daniela; Astori, Cesare; Cazzola, Mario; on Behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators.

In: Oncotarget, Vol. 8, No. 60, 01.01.2017, p. 101735-101744.

Research output: Contribution to journalArticle

Rumi, E, Boveri, E, Bellini, M, Pietra, D, Ferretti, VV, Sant'Antonio, E, Cavalloni, C, Casetti, IC, Roncoroni, E, Ciboddo, M, Benvenuti, P, Landini, B, Fugazza, E, Troletti, D, Astori, C, Cazzola, M & on Behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators 2017, 'Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria', Oncotarget, vol. 8, no. 60, pp. 101735-101744. https://doi.org/10.18632/oncotarget.21594
Rumi, Elisa ; Boveri, Emanuela ; Bellini, Marta ; Pietra, Daniela ; Ferretti, Virginia V. ; Sant'Antonio, Emanuela ; Cavalloni, Chiara ; Casetti, Ilaria C. ; Roncoroni, Elisa ; Ciboddo, Michele ; Benvenuti, Pietro ; Landini, Benedetta ; Fugazza, Elena ; Troletti, Daniela ; Astori, Cesare ; Cazzola, Mario ; on Behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. / Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. In: Oncotarget. 2017 ; Vol. 8, No. 60. pp. 101735-101744.
@article{216362e47631478db7a1ed8c7939aae0,
title = "Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria",
abstract = "The recently revised World Health Organization (WHO) classification of myeloid neoplasms recognizes prefibrotic myelofibrosis (prePMF) as a distinct entity, characterized by well-defined histopathologic features together with minor clinical criteria (leukocytes, anemia, increased LDH, splenomegaly). The aim of the study was to examine the clinical relevance of distinguishing prePMF from essential thrombocythemia (ET). We identified in our database all patients affected with ET, prePMF and primary myelofibrosis (PMF) diagnosed according to 2008 WHO criteria with a bone marrow fibrosis grade 0-1 at diagnosis and one DNA sample to define the mutational status. The bone marrow morphology of all 404 identified patients was reviewed by an expert pathologist and patients were reclassified according to the 2016 WHO criteria. After reclassification, our cohort included 269 ET, 109 prePMF, and 26 myeloproliferative neoplasm unclassificable. In comparison with ET, patients with prePMF had higher leukocyte count, lower hemoglobin level, higher platelet count, higher LDH values, and higher number of circulating CD34-positive cells; they showed more frequently splenomegaly (all P values < ·001). CALR mutations were more frequent in prePMF than in ET (35·8{\%} vs 17·8{\%}, P < ·001). PrePMF patients had shorter overall survival (P < ·001) and a trend to a higher incidence of leukemic evolution (P ·067) compared to ET patients, while they did not differ in terms of thrombotic and bleeding complications. In conclusion, ET and prePMF diagnosed according to 2016 WHO criteria are two entities with a different clinical phenotype at diagnosis and a different clinical outcome.",
keywords = "Diagnostic criteria, Myelofibrosis, Prefibrotic, Thrombocythemia, WHO",
author = "Elisa Rumi and Emanuela Boveri and Marta Bellini and Daniela Pietra and Ferretti, {Virginia V.} and Emanuela Sant'Antonio and Chiara Cavalloni and Casetti, {Ilaria C.} and Elisa Roncoroni and Michele Ciboddo and Pietro Benvenuti and Benedetta Landini and Elena Fugazza and Daniela Troletti and Cesare Astori and Mario Cazzola and {on Behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators}",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.21594",
language = "English",
volume = "8",
pages = "101735--101744",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "60",

}

TY - JOUR

T1 - Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria

AU - Rumi, Elisa

AU - Boveri, Emanuela

AU - Bellini, Marta

AU - Pietra, Daniela

AU - Ferretti, Virginia V.

AU - Sant'Antonio, Emanuela

AU - Cavalloni, Chiara

AU - Casetti, Ilaria C.

AU - Roncoroni, Elisa

AU - Ciboddo, Michele

AU - Benvenuti, Pietro

AU - Landini, Benedetta

AU - Fugazza, Elena

AU - Troletti, Daniela

AU - Astori, Cesare

AU - Cazzola, Mario

AU - on Behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The recently revised World Health Organization (WHO) classification of myeloid neoplasms recognizes prefibrotic myelofibrosis (prePMF) as a distinct entity, characterized by well-defined histopathologic features together with minor clinical criteria (leukocytes, anemia, increased LDH, splenomegaly). The aim of the study was to examine the clinical relevance of distinguishing prePMF from essential thrombocythemia (ET). We identified in our database all patients affected with ET, prePMF and primary myelofibrosis (PMF) diagnosed according to 2008 WHO criteria with a bone marrow fibrosis grade 0-1 at diagnosis and one DNA sample to define the mutational status. The bone marrow morphology of all 404 identified patients was reviewed by an expert pathologist and patients were reclassified according to the 2016 WHO criteria. After reclassification, our cohort included 269 ET, 109 prePMF, and 26 myeloproliferative neoplasm unclassificable. In comparison with ET, patients with prePMF had higher leukocyte count, lower hemoglobin level, higher platelet count, higher LDH values, and higher number of circulating CD34-positive cells; they showed more frequently splenomegaly (all P values < ·001). CALR mutations were more frequent in prePMF than in ET (35·8% vs 17·8%, P < ·001). PrePMF patients had shorter overall survival (P < ·001) and a trend to a higher incidence of leukemic evolution (P ·067) compared to ET patients, while they did not differ in terms of thrombotic and bleeding complications. In conclusion, ET and prePMF diagnosed according to 2016 WHO criteria are two entities with a different clinical phenotype at diagnosis and a different clinical outcome.

AB - The recently revised World Health Organization (WHO) classification of myeloid neoplasms recognizes prefibrotic myelofibrosis (prePMF) as a distinct entity, characterized by well-defined histopathologic features together with minor clinical criteria (leukocytes, anemia, increased LDH, splenomegaly). The aim of the study was to examine the clinical relevance of distinguishing prePMF from essential thrombocythemia (ET). We identified in our database all patients affected with ET, prePMF and primary myelofibrosis (PMF) diagnosed according to 2008 WHO criteria with a bone marrow fibrosis grade 0-1 at diagnosis and one DNA sample to define the mutational status. The bone marrow morphology of all 404 identified patients was reviewed by an expert pathologist and patients were reclassified according to the 2016 WHO criteria. After reclassification, our cohort included 269 ET, 109 prePMF, and 26 myeloproliferative neoplasm unclassificable. In comparison with ET, patients with prePMF had higher leukocyte count, lower hemoglobin level, higher platelet count, higher LDH values, and higher number of circulating CD34-positive cells; they showed more frequently splenomegaly (all P values < ·001). CALR mutations were more frequent in prePMF than in ET (35·8% vs 17·8%, P < ·001). PrePMF patients had shorter overall survival (P < ·001) and a trend to a higher incidence of leukemic evolution (P ·067) compared to ET patients, while they did not differ in terms of thrombotic and bleeding complications. In conclusion, ET and prePMF diagnosed according to 2016 WHO criteria are two entities with a different clinical phenotype at diagnosis and a different clinical outcome.

KW - Diagnostic criteria

KW - Myelofibrosis

KW - Prefibrotic

KW - Thrombocythemia

KW - WHO

UR - http://www.scopus.com/inward/record.url?scp=85034813488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034813488&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.21594

DO - 10.18632/oncotarget.21594

M3 - Article

VL - 8

SP - 101735

EP - 101744

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 60

ER -